Sevelamer Hydrochloride for Tumor Lysis Syndrome-related Hyperphosphatemia

*, Harsha Prasada L (2015) Sevelamer Hydrochloride for Tumor Lysis Syndrome-related Hyperphosphatemia. Indian Pediatrics, 52. pp. 613-615. ISSN 0019-6061

[img] PDF
613.pdf - Published Version
Restricted to Repository staff only

Download (53kB) | Request a copy


Background: Tumour lysis syndrome is associated with high levels of uric acid, phosphate and potassium along with low levels of calcium and abnormal renal function. Sevelamer, an oral phosphate-binder is used in the treatment of hyperphosphatemia in children and adults on hemodialysis. Case characteristics: Two children with T-cell acute lymphoblastic leukemia who presented with a high tumour load and developed tumour lysis syndrome. Observation: Both children received Rasburicase and Sevelamer hydrochloride. The serum phosphate reduced to normal levels within 24-48 hrs of initiation of sevelamer hydrochloride. Message: Sevelamer appears to be an effective treatment for hyperphosphatemia associated with tumour lysis syndrome.

Item Type: Article
Uncontrolled Keywords: Acute lymphoblastic leukemia, Hyperphosphatemia, Sevelamer hydrochloride, Tumour lysis syndrome
Subjects: Medicine > KMC Mangalore > Paediatrics
Depositing User: KMCMLR User
Date Deposited: 22 Aug 2016 12:09
Last Modified: 22 Aug 2016 12:09

Actions (login required)

View Item View Item